Please login to the form below

Not currently logged in
Email:
Password:

Takeda acquires Nycomed

Takeda Pharmaceutical Company has completed a €9.6bn takeover of Nycomed

Takeda Pharmaceutical Company has acquired Nycomed for €9.6bn on a cash-free, debt-free basis.

The boards of directors of each company unanimously approved the transaction that is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed's US dermatology business.

Takeda said: "This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011–2013 mid-range plan. Takeda has its strong presence in the Japanese and US markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialisation capability."

The acquisition includes the roflumilast franchise, a first-in-class treatment for chronic obstructive pulmonary disease, which is expected to be a major source of revenue growth for Takeda.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics